FIG. 6.

In vivo tumor-killing efficacy of HF-LPLI in ASTC-a-1-transplanted tumor model. (A, B) Effects of HF-LPLI on ASTC-a-1-transplanted tumors in nude mice. (A) Volumetric change in tumor sizes induced by HF-LPLI at different laser doses. The data represent the mean±SD (n=10). *P<0.05 versus control. (B) Kaplan–Meier survival curves show the survival rates of the tumor-bearing mice that received HF-LPLI or PDT (n=20). Representative images of the mice that received HF-LPLI or PDT were also shown (inset). (C) Representative images of H&E-stained specimens at×10 magnification, and annexin V-FITC staining analysis of tumor 1 day after HF-LPLI treatment. (D) Volumetric change in tumor sizes induced by HF-LPLI in ρ⁰ASTC-a-1 tumor. The data represent the mean±SD (n=10). (E) In vivo monitoring of O₂^−• generation in ASTC-a-1 and ρ⁰ASTC-a-1 tumors using FCLA-based CL after HF-LPLI treatment. FCLA was injected subcutaneously into the HF-LPLI-CL measurement site of the tumor 1 h before light irradiation to allow for adequate absorption. SOD was used to scavenge the O₂^−• generated by HF-LPLI. The data represent the mean±SD (n=5). *P<0.05 versus control. (F) Representative images of TUNEL- and DAB-stained specimens harvested 1 h after HF-LPLI treatment. CL, chemiluminescence; DAB, 3,3′-diaminobenzidine; H&E, hematoxylin and eosin; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars